Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
23-valent pneumococcal polysaccharide vaccine + influenza vaccine
- Development stage
- Unknown
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This entry refers to the co-administration of Sinovac Biotech's 23-valent pneumococcal polysaccharide vaccine (PPV23) and a seasonal influenza vaccine. The PPV23 component is an inactivated vaccine containing purified capsular polysaccharides from 23 serotypes of *Streptococcus pneumoniae*, designed to provide broad protection against invasive pneumococcal diseases such as pneumonia, meningitis, and bacteremia. The influenza vaccine component (typically Sinovac's Anflu) is an inactivated vaccine intended to prevent seasonal influenza caused by circulating A and B virus strains. Clinical studies, such as NCT03341104, have evaluated the safety and immunogenicity of administering these two vaccines simultaneously to improve vaccination efficiency and coverage in target populations, including individuals aged 2 years and older.
- Other names
- Sinovac PPV23 + Influenza Vaccine23-valent pneumococcal polysaccharide vaccineInfluenza vaccine
02
Targets
HA (Hemagglutinin)CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on 23-valent pneumococcal polysaccharide vaccine + influenza vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 23-valent pneumococcal polysaccharide vaccine + influenza vaccine.